Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$12.73
-0.05 (-0.39%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-168.9M · quality 46.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$10.5B
P/E
50.9x
↑EV/EBITDA
19.0x
↑ROE
4.5%
↑Gross Margin
51.0%
↑Debt/Equity
0.17
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-8.5%
FCF CAGR
-28.8%
FCF margin
8.0%
FCF / Net income
1.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.74B · net income $195.6M · FCF $219.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.74B | $2.74B | $2.87B | $3.28B | $3.58B |
| Net Income | $195.6M | $195.6M | $183.8M | $209.7M | $307.3M |
| EBITDA | $547.8M | $547.8M | $480.6M | $528.9M | $629.3M |
| EPS | 0.24 | 0.24 | 0.22 | 0.25 | 0.38 |
| Gross Margin | 51.0% | 51.0% | 47.1% | 44.9% | 42.9% |
| Operating Margin | 14.2% | 14.2% | 14.4% | 15.5% | 16.2% |
| Net Margin | 7.1% | 7.1% | 6.4% | 6.4% | 8.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.17 | 0.17 | 0.19 | 0.16 | 0.13 |
| Current Ratio | 1.71 | 1.71 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $219.0M | $219.0M | $-168.9M | $-235.0M | $606.9M |
| Returns | |||||
| ROE | 4.5% | 4.5% | 4.1% | 4.4% | 6.5% |
| Valuation | |||||
| P/E | 50.92 | 50.92 | 54.78 | 69.68 | 46.66 |
| EV/EBITDA | 18.96 | 18.96 | 21.17 | 27.84 | 22.17 |
| P/B | 2.41 | 2.41 | 2.25 | 3.06 | 3.02 |
| Growth & Yield | |||||
| Revenue Growth | -4.5% | -4.5% | -12.4% | -8.6% | — |
| EPS Growth | 6.4% | 6.4% | -12.3% | -33.1% | — |
| Dividend Yield | 0.6% | 0.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
68.2%
EPS terminal req.
$1.13
Spread vs growth
-61.8%
5Y implied EPS CAGR
41.9%
EPS terminal req.
$1.37
Spread vs growth
-35.5%
10Y implied EPS CAGR
25.0%
EPS terminal req.
$2.20
Spread vs growth
-18.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-9.1%
Start / end P/E
63.3x → 53.7x
EPS bridge
0.22 → 0.24
Residual
-1.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.